BioHarvest Sciences Inc.
corporate_fare Company Profile
BioHarvest Sciences Inc. (NASDAQ:BHST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for BHST at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BHST spans 6-K.
Recent high-impact activity:
- Q3 Revenue Falls to $7.9M, Cash Drops to $12.5M as 2026 Guidance Is Cut
- BioHarvest Q3 Revenue Falls to $7.9M; Going-Concern Warning on $12.5M Cash
- BioHarvest's Olive Cell Asset Hits Commercial Readiness, Opens CDMO Licensing
- BioHarvest Authorizes Buyback of Up to 5% of Shares, Citing Undervaluation
- BioHarvest Q2 Revenue Hits $8.8M, Gross Margin 58%; CDMO Deal Secures 20-Ton Fragrance Production
Financial Snapshot
Short Interest & Short Volume
5.06 days to coverFINRA reported short interest of 75,571 shares in BHST as of the October 30, 2026 settlement, a 16.2% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 54.6% of BHST volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
BHST files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.